Literature DB >> 12639611

Parvovirus B19 and autoimmune diseases.

Olivier Meyer1.   

Abstract

Parvovirus B19 (B19) causes many clinical disorders, of which the most common are erythema infectiosum, aplastic crisis complicating chronic hemolytic anemia, and hydrops fetalis. In young adults, the skin eruption caused by B19 is accompanied with polyarthritis and polyarthralgia in 60% of the cases. The joint abnormalities predominate in the hands and feet and usually resolve within a week (range 2-21 d). Serological tests show IgM antibodies against B19, confirming the diagnosis of recent infection. Protracted polyarthritis occurs in some patients and seems associated with the DR4 histocompatibility alleles. Rheumatoid factors can be produced transiently in these patients. Other autoantibodies produced in the wake of B19 infection include anti-nuclear antibodies, anti-DNA, anti-SSA/SSB, and anti-phospholipids. Acute B19 infection can simulate early rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) (lupus-like eruption over the cheeks, cytopenia, etc.). In addition, there have been a few reports of erosive RA or SLE developing shortly after a B19 infection, with positive PCR tests for B19 DNA in synovial tissue or blood cells. Studies in large series indicate that B19 is probably an extremely rare cause of RA or SLE. Vasculitides affecting the small vessels (Henoch-Schonlein purpura, Wegener's granulomatosis), medium-sized vessels (periarteritis nodosa), and large vessels (giant cell arteritis) can occur after B19 infection. Here again, the number of clinical cases is small.

Entities:  

Mesh:

Year:  2003        PMID: 12639611     DOI: 10.1016/s1297-319x(02)00004-0

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  21 in total

1.  Parvovirus infection mimicking systemic lupus erythematosus.

Authors:  Mohan Cooray; Joshua J Manolakos; Douglas S Wright; Shariq Haider; Ameen Patel
Journal:  CMAJ       Date:  2013-08-26       Impact factor: 8.262

2.  A case of pure red cell aplasia and systemic lupus erythematosus caused by human parvovirus B19 infection.

Authors:  Haruko Ideguchi; Shigeru Ohno; Yoshiaki Ishigatsubo
Journal:  Rheumatol Int       Date:  2006-10-07       Impact factor: 2.631

Review 3.  The influence of early life factors on the risk of developing rheumatoid arthritis.

Authors:  A N Colebatch; C J Edwards
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

Review 4.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  Human parvovirus B19 nonstructural protein NS1 enhanced the expression of cleavage of 70 kDa U1-snRNP autoantigen.

Authors:  Bor-Show Tzang; Der-Yuan Chen; Chun-Chou Tsai; Szu-Yi Chiang; Tsung-Ming Lin; Tsai-Ching Hsu
Journal:  J Biomed Sci       Date:  2010-05-25       Impact factor: 8.410

Review 6.  Rheumatoid arthritis is linked to Proteus--the evidence.

Authors:  Taha Rashid; Alan Ebringer
Journal:  Clin Rheumatol       Date:  2007-01-06       Impact factor: 3.650

7.  Does parvovirus infection have a role in systemic lupus erythematosus?

Authors:  Tami Hod; Giselle Zandman-Goddard; Pnina Langevitz; Hagit Rudnic; Zehava Grossman; Pnina Rotman-Pikielny; Yair Levy
Journal:  Immunol Res       Date:  2017-04       Impact factor: 4.505

8.  Human parvovirus B19 induced apoptotic bodies contain altered self-antigens that are phagocytosed by antigen presenting cells.

Authors:  Kanoktip Thammasri; Sanna Rauhamäki; Liping Wang; Artemis Filippou; Violetta Kivovich; Varpu Marjomäki; Stanley J Naides; Leona Gilbert
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

9.  Seroprevalence of parvovirus B19 in fibromyalgia syndrome.

Authors:  Mehves Buyukkose; Erkan Kozanoglu; Sibel Basaran; Ozlem Bayramoglu; Fugen Yarkin
Journal:  Clin Rheumatol       Date:  2008-12-05       Impact factor: 3.650

Review 10.  Infection and Lupus: Which Causes Which?

Authors:  Sarah Doaty; Harsh Agrawal; Erin Bauer; Daniel E Furst
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.